Dapafort BP
Coated tablets
Trade name
Dapafort BP
Active ingridient
Dapagliflozin
Descritpion and Composition
DapaFORT-BP by Balkan Pharmaceuticals is an advanced oral antihyperglycemic agent belonging to the selective sodium-glucose co-transporter 2 (SGLT2) inhibitor class. Its active substance, dapagliflozin, is indicated for adults with type 2 diabetes mellitus, administered as monotherapy or adjunct to other antidiabetic therapies to maintain consistent and targeted glycemic control.Active substance: Dapagliflozin (5 mg or 10 mg per film-coated tablet).
Mechanism of Action: Selectively blocks the renal SGLT2 transporter, suppressing glucose reabsorption in the kidneys and promoting urinary glucose excretion, thereby reducing plasma glucose levels independently of insulin secretion.
Available Strengths:
5 mg: Baseline dose indicated for treatment initiation or moderate glycemic control.
10 mg: Standard maintenance dose for intensive glycemic management or enhanced combination regimens.
Key Advantages: Once-daily oral administration, high digestive tolerability, optimal bioavailability.
Presentation: Pack of 30 film-coated tablets (3 blisters of 10 tablets each).
Storage: Store below 25 °C in the original package. Prescription-only medicine.